MedTrace Logo

Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone

NCT00480844 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-03-25

No results posted yet for this study

Summary

In this study we intend to compare the effect of Sertindole to that of Risperidone on cognitive impairment in schizophrenia.

Hypothesis: Sertindole will be as effective as Risperidone for treating cognitive impairment in schizophrenia and with fewer side effects.

Conditions

Interventions

DRUG

Sertindole

Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.

DRUG

Risperidone

Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Mark Weiser, Dr · Shaba Medical Center, Tel-Aviv University Sackler School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-10-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00480844 on ClinicalTrials.gov